ONO Pharmaceutical Co., Ltd.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. carries a market capitalization of 4.67B, placing it among publicly traded companies globally. Its enterprise value stands at 4.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ONO Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. has 469.77M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, ONO Pharmaceutical Co., Ltd. recorded an income tax benefit of -6.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, ONO Pharmaceutical Co., Ltd.'s stock has gained approximately 37.86% over the past 52 weeks. The 50-day moving average sits at 13.25, while the 200-day moving average is 13.06.

As of March 31, 2025, ONO Pharmaceutical Co., Ltd. holds 1.30B in cash and equivalents against 904.31M in total debt, resulting in a net debt position of -428.90M. Total book value stands at 4.82B, with working capital of 1.89B providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, ONO Pharmaceutical Co., Ltd. paid dividends of 0.01 per share.

ONO Pharmaceutical Co., Ltd.'s most recent stock split took place on March 29, 2016 with a 1:5 split ratio.